Obinutuzumab

CD20-directed Cytolytic Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Obinutuzumab is a drug in the CD20-directed Cytolytic Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as CD20-directed Antibody Interactions. DrugCentral lists 1 molecular target, including MS4A1. Recorded indications include CD20-positive follicular lymphoma and Chronic lymphoid leukemia, disease.

• Drug class: CD20-directed Cytolytic Antibody.
• Mechanism of action: CD20-directed Antibody Interactions.
• Molecular targets: MS4A1 (1 listed in DrugCentral).
• Indications: CD20-positive follicular lymphoma and Chronic lymphoid leukemia, disease.
• ATC code: L01FA03 (CD20 (Clusters of Differentiation 20) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• CD20-positive follicular lymphoma
• Chronic lymphoid leukemia, disease

Mechanism & targets

• Mechanism of action (MoA): CD20-directed Antibody Interactions
• Established pharmacologic class: CD20-directed Cytolytic Antibody

Molecular targets (1)

Target	Gene	Action	Activity
B-lymphocyte antigen CD20	MS4A1	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2018-07-02	PMDA	—	Chugai Pharmaceutical Co., Ltd.
2014-07-23	EMA	—	—	Yes
2013-11-01	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
L01FA03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › CD20 (Clusters of Differentiation 20) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: MS4A1
• FDA label: MS4A1
• HCSC label: MS4A1

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
COVID-19	1562.8
Neutropenia	1448.9
Febrile neutropenia	961.3
Disease progression	958.5
Cytokine release syndrome	955.2
Myelosuppression	927.3
Tumour lysis syndrome	863.8
No adverse event	729.3
Off label use	728.2
Infusion related reaction	723.6
COVID-19 pneumonia	655.9
Thrombocytopenia	652.2

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 949142-50-1
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Obinutuzumab used for?

DrugCentral lists the following indications for Obinutuzumab: CD20-positive follicular lymphoma and Chronic lymphoid leukemia, disease.

How does Obinutuzumab work?

Obinutuzumab is classified as CD20-directed Antibody Interactions; its molecular targets in DrugCentral include MS4A1.

When was Obinutuzumab first approved?

Obinutuzumab was first approved by the FDA in 2013.

What drug class does Obinutuzumab belong to?

Obinutuzumab is in the CD20-directed Cytolytic Antibody class.

Sources

• DrugCentral drug card 4983 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1743048 — compound record and bioactivity
• DrugBank DB08935 — drug record
• FDA UNII O43472U9X8 — substance identity
• DailyMed: FDA labels for Obinutuzumab — current prescribing information (label search)
• UniProt P11836 (MS4A1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.